ADC Therapeutics S.A.
ADCT · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $71 | $70 | $210 | $34 |
| % Growth | 1.8% | -66.9% | 518.9% | – |
| Cost of Goods Sold | $6 | $3 | $3 | $1 |
| Gross Profit | $65 | $67 | $207 | $33 |
| % Margin | 91.6% | 96.4% | 98.4% | 95.9% |
| R&D Expenses | $110 | $127 | $186 | $158 |
| G&A Expenses | $64 | $73 | $108 | $71 |
| SG&A Expenses | $86 | $106 | $143 | $136 |
| Sales & Mktg Exp. | $21 | $33 | $36 | $65 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $196 | $233 | $330 | $294 |
| Operating Income | -$131 | -$166 | -$123 | -$262 |
| % Margin | -184.4% | -238.6% | -58.8% | -771.6% |
| Other Income/Exp. Net | -$27 | -$35 | -$34 | $10 |
| Pre-Tax Income | -$158 | -$201 | -$157 | -$252 |
| Tax Expense | $0 | $39 | $0 | -$21 |
| Net Income | -$158 | -$240 | -$157 | -$230 |
| % Margin | -222.8% | -345.1% | -74.9% | -678.2% |
| EPS | -1.62 | -2.94 | -1.99 | -3 |
| % Growth | 44.9% | -47.7% | 33.7% | – |
| EPS Diluted | -1.62 | -2.94 | -1.99 | -3 |
| Weighted Avg Shares Out | 97 | 82 | 78 | 77 |
| Weighted Avg Shares Out Dil | 97 | 82 | 78 | 77 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12 | $11 | $3 | $0 |
| Interest Expense | $50 | $46 | $37 | $18 |
| Depreciation & Amortization | $3 | $3 | $2 | $3 |
| EBITDA | -$103 | -$146 | -$108 | -$231 |
| % Margin | -144.9% | -209.6% | -51.3% | -679.7% |